

Low frequency of type-I and type-II aberrations in myeloid leukemia of Down syndrome, underscoring the unique entity of this disease

Marjolein Blink,¹ Marry M. van den Heuvel-Eibrink,¹ Valerie de Haas,² Jan-Henning Klusmann,³ Henrik Hasle,⁴ and C. Michel Zwaan¹

¹Department of Pediatric Oncology/Hematology, Erasmus MC–Sophia Children’s Hospital Rotterdam, The Netherlands; ²Dutch Childhood Oncology Group, The Hague, The Netherlands; ³Department of Pediatric Oncology/Hematology, AML-BFM Study Group, Medical High School, Hannover, Germany; and ⁴Department of Pediatrics, Nordic Society for Pediatric Hematology and Oncology (NOPHO), Aarhus University Hospital Skejby, Aarhus, Denmark

Citation: Low frequency of type-I and type-II aberrations in myeloid leukemia of Down syndrome, underscoring the unique entity of this disease. Blink M, van den Heuvel-Eibrink MM, de Haas V, Klusmann J-H, Hasle H, and Zwaan CM. *Haematologica* 2012;97(4):632-634. doi:10.3324/haematol.2011.057505

Online Supplementary Table S1. Hotspot regions, primers and PCR conditions for the investigated genes.

Gene*	Region / Exon	Primer sequences	PCR conditions**
<i>NPM1</i> ¹	exon 12	5'-CTGGTGGTAGAATGAAAATAGAT-3' 5'-GGCAGGGACATTCTCATAG-3'	1
<i>CEBPA</i> ²	whole gene	5'-CGCCATGCCGGGAGAACTCT-3'	2
		5'-CTTGGCTTCATCCTCCTCGC-3'	
		5'-CGGCCGCTGGTGATCAAG-3'	3
		5'-CCAGGGCGTCCCACAGC-3'	
<i>MLL</i> ³	specific PTD's	5'-AGGAGAGAGTTTACCTGCTC-3' 5'-GGAAGTCAAGCAAGCAGGTC-3'	1
<i>WT1</i> ⁴	exon 7	5'-CATGGGGATCTGGAGTGTGA-3' 5'-TGGGTCTTAGCAGTGTGAGA-3'	1
	exon 9	5'-TAGGGCCGAGGCTAGACC-3' 5'-TTCCAATCCCTCTCATACAAT-3'	1
<i>FLT3</i> ⁵	exon 14/15 (ITD)	5'-GCAATTTAGGTATGAAAGCCAGC-3' 5'-CTTTCAGCATTTTGACGGCAACC-3'	1
	exon 20 (TKD)	5'-TCACCG GTACCTCCTACTG-3' 5'-AAATGCACCACAGTGAGTG-3'	1
<i>N-RAS</i> ⁶	exon 2	5'-GGGGTTGCTAGAAAACATA-3' 5'-ATCCGACAAGTGAGAGACA-3'	1
	exon 3	5'-CCCAGGATCTTACAGAAAA-3' 5'-TCCCCATAAAGATTGAGAAC-3'	1
<i>K-RAS</i> ⁶	exon 2	5'-CGTCGATGGAGGAGTTT-3' 5'-AACCCAAGGTACATTTGAGA-3'	1
<i>PTPN1</i> ⁶	exon 3	5'-TTGGGTTTCTTTCAACACTT-3' 5'-GCCTTTGGAGTCAGAGAGT-3'	1
	exon 13	5'-TGGCTCTGCAGTTTCTCT-3' 5'-CATTCCGAAATCAAACAGTT-3'	1
<i>KIT</i> ⁶	exon 8	5'-CCGCCTCTGTACTCT-3' 5'-TTCAGCAAAACAAATTAATGTCTA-3'	4
	exon 17	5'-TCCTCCAACCTAATAGTGATTC-3' 5'-CATTCCGAAATCAAACAGTT-3'	4
<i>IDH1</i>	exon 4	5'-TTGGGAATTGATTAAGAGAAA-3' 5'-CACACCTTCTTCAAAGTTATG-3'	1
<i>IDH2</i>	exon 4	5'-AACCGTGACCAGACTGATG-3' 5'-GTTCTTGGTGCTCATGTACAG-3'	1
<i>DNMT3A</i> ⁷	exon 12-23	5'-GCCACCAGAAGAAGAGAAGA-3'	1
		5'-GCACCTGCAGCAGTTGT-3'	
		5'-CCGGAACATTGAGGACA-3'	1
		5'-CTGGACAGGTGGGTTAA-3'	
		5'-CGGAGGTGTGAGGACT-3'	1
		5'-GTTTCATACCGGAAGGTTAC-3'	
		5'-CTCCAGATGTTCTTCGCTAA-3'	1
		5'-CCACTCCTGGATATGCTTCT-3'	

*Superscript numbers refer to the below mentioned papers in which the methods were fully described. ** numbers refer to the following PCR programs:

¹10' 95°C, 40 cycles of 1' 95°C and 1' 60°C, 10' 72°C.

²10' 95°C, 35 cycles of 1' 95°C, 1' 60°C and 1' 72°C, 10' 72°C.

³10' 95°C, touchdown 20 cycles of 1' 95°C, 1' 70-60°C and 1' 72°C plus 20 cycles of 1' 95°C, 1' 60°C and 1' 72°C, 10' 72°C.

⁴10' 95°C, touchdown 20 cycles of 1' 95°C, 1' 66-56°C and 1' 72°C plus 14 cycles of 1' 95°C, 1' 56°C and 1' 72°C, 10' 72°C.

References

- Hollink IH, Zwaan CM, Zimmermann M, Arentsen-Peters TC, Pieters R, Cloos J, et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. *Leukemia*. 2009;23(2):262-70.
- Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Zimmermann M, Peeters JK, Valk PJ, et al. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. *Haematologica*. 2011;96(3):384-92. PMID:3046269.
- Balgobind BV, Hollink IH, Reinhardt D, van Wering ER, de Graaf SS, Baruchel A, et al. Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique. *Eur J Cancer*. 2010;46(10):1892-9.
- Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, Balgobind BV, Arentsen-Peters ST, Alders M, et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. *Blood*. 2009;113(23):5951-60.
- Stam RW, den Boer ML, Schneider P, Nollau P, Horstmann M, Beverloo HB, et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. *Blood*. 2005;106(7):2484-90.
- Balgobind BV, Van Vlierberghe P, van den Ouweland AM, Beverloo HB, Terlouw-Kromosoeto JN, van Wering ER, et al. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. *Blood*. 2008;111(8):4322-8.
- Hollink IH, Feng Q, Danen-van Oorschot AA, Arentsen-Peters ST, Verboon LJ, Zhang P, et al. Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model. *Leukemia*. 2012;26(2):371-3.